Nuclear Medicine Imaging Equipment MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy ConfigurationBy End UserBy Component
Full title & scope — all 5 axes with their segments
Nuclear Medicine Imaging Equipment Market Size, Share & Industry Analysis, By Type (Full Ring PET Scanners, Partial Ring PET Scanners), By Application (Oncology, Cardiology, Others), By Configuration (PET/CT Hybrid Systems, Standalone PET Systems, PET/MRI Hybrid Systems), By End User (Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes), By Component (Systems, Software & Reconstruction Solutions, Services & Maintenance), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.

- 01By TypeFull Ring PET Scanners · Partial Ring PET Scanners
- 02By ApplicationOncology · Cardiology · Others
- 03By ConfigurationPET/CT Hybrid Systems · Standalone PET Systems · PET/MRI Hybrid Systems
- 04By End UserHospitals · Diagnostic Imaging Centers · Academic & Research Institutes
- 05By ComponentSystems · Software & Reconstruction Solutions · Services & Maintenance
- 06By Region
Market Analysis & Outlook
Nuclear medicine imaging equipment covers the scanners used to visualize physiological and metabolic activity inside the body by detecting radiation emitted from a small dose of radioactive tracer administered to the patient, most commonly positron emission tomography (PET) systems sold as standalone units or combined with computed tomography or magnetic resonance imaging in a single hybrid system. Buyers are hospitals, dedicated diagnostic imaging centers and academic or research medical centers that use these scans primarily to stage and monitor cancer treatment, alongside smaller volumes of cardiac and neurological studies.
Growth of 8.51% a year carries the global nuclear medicine imaging equipment market from USD 6.9 billion in 2025 to USD 14.31 billion in 2034. The full series behind that rate covers USD 4.7 billion in 2020, USD 6.39 billion in 2024, USD 7.45 billion in 2026 and USD 10.32 billion in 2030, with 2025 as the base year.
On the type axis, growth rates run from 7.67% for Full Ring PET Scanners up to 10.13% for Partial Ring PET Scanners. Full Ring PET Scanners carries the volume: USD 4.69 billion and 68% of revenue in 2025, USD 9.16 billion and 64% in 2034. The lines gaining share are Partial Ring PET Scanners. Full Ring PET Scanners lose share without losing revenue.
By application, Oncology accounts for 62% of 2025 revenue at USD 4.28 billion, reaching USD 9.3 billion and 65% by 2034. It is also the fastest-growing line on this axis at 9%, so the split concentrates over the period instead of balancing. This axis divides the same revenue as the type split instead of adding to it, so the two are read together and never summed.
North America is the largest region at 38% of 2025 revenue, worth USD 2.62 billion and reaching USD 4.87 billion by 2034. Europe follows at 27%, moving from USD 1.86 billion to USD 3.58 billion, and Middle East and Africa is the smallest at 5.1%. Because Asia Pacific take share, the revenue added by 2034 concentrates instead of spreading across all five regions.
Behind these figures sit five regions, two type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 8.51% takes the market from USD 6.9 billion in 2025 to USD 14.31 billion in 2034, against 7.98% recorded over the 2020-2025 historical period.
- The largest line by type is Full Ring PET Scanners, worth USD 4.69 billion and 68% of revenue in 2025, rising to USD 9.16 billion and 64% by 2034.
- At 10.13%, Partial Ring PET Scanners grows faster than any other type line, moving from USD 2.21 billion and 32% of revenue in 2025 to USD 5.15 billion and 36% in 2034.
- Scenario range for 2034 runs from USD 12.16 billion in the bear case to USD 16.46 billion in the bull case, against a base-case USD 14.31 billion, the spread a plan built on this forecast has to absorb.
- North America holds 38% of global revenue in 2025 at USD 2.62 billion, the largest of the five regions tracked, and reaches USD 4.87 billion by 2034.
- The United States accounts for 85.1% of North America in the base year, worth USD 2.23 billion in 2025 and reaching USD 4.14 billion by 2034, the worked country example carried through that region's chapters.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By by type
Base year 2025Full Ring PET Scanners leads with 68.0% of by type segment revenue.
Share of by type segment revenue, most recent base year.
The global nuclear medicine imaging equipment market is shaped over 2026-2034 by three measurable movements: a change in the type mix, a shift in where revenue sits geographically, and the 8.51% rate carrying the total.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Composition shifts on the type axis. Partial Ring PET Scanners grows at 10.13% across 2026-2034 against 7.67% for Full Ring PET Scanners, the widest spread on the type axis. Over the forecast period that moves Partial Ring PET Scanners from 32% of revenue to 36%, and Full Ring PET Scanners from 68% to 64%. Neither contracts: USD 2.21 billion becomes USD 5.15 billion, USD 4.69 billion becomes USD 9.16 billion. What the spread decides is which of them a supplier's revenue is exposed to.
Growth concentrates in Asia Pacific. Asia Pacific moves from 24.1% of revenue in 2025 to 30% in 2034, worth USD 1.66 billion rising to USD 4.29 billion. The remaining regions grow in absolute terms while giving up share: North America at 38% moving to 34%, Europe at 27% moving to 25%, Latin America at 5.9% moving to 5.9%, Middle East and Africa at 5.1% moving to 5%. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.
Growth compounds at 8.51% without a step change. Fifteen years of revenue run USD 4.7 billion in 2020, USD 6.39 billion in 2024, USD 6.9 billion in 2025, USD 7.45 billion in 2026, USD 10.32 billion in 2030 and USD 14.31 billion in 2034. There is no discontinuity to time, and 8.51% forecast growth against 7.98% historical means the trend continues and does not turn. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the type and regional mixes matter more to a forecast than the headline rate does.
Market Growth Factors
Growth is concentrated in Partial Ring PET Scanners
Market Drivers
3- 01Growth is concentrated in Partial Ring PET Scanners
The fastest line on the type axis is Partial Ring PET Scanners, at 10.13% against the market's 8.51%, taking USD 2.21 billion to USD 5.15 billion and 32% of revenue to 36%. Because the spread to Full Ring PET Scanners at 7.67% is this wide, the headline 8.51% is a weighted result, not a rate any single line achieves. That makes position on the type axis a growth decision, not a product one.
- 02Regional weight, not regional count
38% of 2025 revenue (USD 2.62 billion) is generated in North America, reaching USD 4.87 billion by 2034 at an unchanged 34%. Europe adds a further 27% at USD 1.86 billion, reaching USD 3.58 billion. Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.
- 03The trend is already in the record
The historical period compounded at 7.98%; USD 4.7 billion in 2020, USD 6.39 billion in 2024 and USD 6.9 billion in 2025. The forecast period then runs at 8.51%, ending 2034 at USD 14.31 billion. With the trajectory already demonstrated over fifteen years, what remains uncertain is the mix, not the direction, which is where the segment and regional sections do the work.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising global cancer incidence expanding oncology PET scan volumes | High | +2.6 | High | High | Medium |
| 2 | Expanding radiopharmaceutical and theranostics tracer pipelines beyond FDG | High | +1.8 | Medium | High | High |
| 3 | Government and private investment in Asia Pacific imaging infrastructure | Medium-High | +1.4 | High | Medium | Medium |
| 4 | Replacement and upgrade cycle across the aging PET/CT installed base | Medium | +1 | Medium | Medium | Low |
| 5 | Growth of outpatient diagnostic imaging centers expanding patient access | Medium | +0.7 | Low | Medium | Medium |
| 6 | Others | Low | +0.35 | Low | Low | Low |
| Total | +7.85 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High capital and facility costs limiting adoption in smaller and lower-income markets | Medium-High | −0.3 | High | Medium | Medium |
| 2 | Radioisotope supply constraints and short half-life logistics | Medium | −0.14 | Medium | Medium | Low |
| Total | −0.44 | |||||
Drivers contribute 7.85 Billion and restraints remove 0.44 Billion, a net 7.41 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 8.51% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
What holds the forecast back
Market Restraints
2- 01What holds the forecast back
A bear case of USD 12.16 billion in 2034, against USD 14.31 billion in the base case, rests on one stated assumption: bear case assumes a radioisotope supply disruption or a reimbursement policy delay in one or more major markets that slows procedure growth and pushes planned system replacements into later years. Neither case changes the USD 6.9 billion 2025 base.
- 02The largest line is not the fastest
Full Ring PET Scanners carries 68% of 2025 revenue at USD 4.69 billion but compounds at 7.67% against 8.51% for the market, taking its share to 64% by 2034 even as revenue rises to USD 9.16 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Upside case: USD 16.46 billion by 2034
Market Opportunities
2- 01Upside case: USD 16.46 billion by 2034
Bull case assumes faster-than-expected approval and reimbursement rollout for next-generation PET radiotracers beyond oncology, pulling forward replacement demand and expanding scan volumes across all five regions. On that assumption the market reaches USD 16.46 billion by 2034 against USD 14.31 billion in the base case, from the same USD 6.9 billion in 2025.
- 02The opening is on the type axis, not the regional one
Share on the type axis moves toward Partial Ring PET Scanners, from 32% in 2025 to 36% in 2034, on 10.13% growth against the market's 8.51% and revenue rising from USD 2.21 billion to USD 5.15 billion. Taking position there does not require displacing whoever holds Full Ring PET Scanners, which is the harder and more expensive fight.
Market Challenges
Revenue is concentrated in Full Ring PET Scanners
Market Challenges
2- 01Revenue is concentrated in Full Ring PET Scanners
One line dominates: Full Ring PET Scanners, at 68% of revenue in 2025 and 64% in 2034, worth USD 4.69 billion and USD 9.16 billion. That concentration means the market's own forecast is, to a large extent, a forecast for one type line.
- 02North America is largely the United States
85.1% of the leading region is one country: the United States, at USD 2.23 billion against North America's USD 2.62 billion in 2025, and USD 4.14 billion by 2034. Read as a region it looks diversified; read by weight it is not, and the regional forecast inherits whatever happens in that one market.
Segmentation Analysis
5 axesThe global nuclear medicine imaging equipment market is cut five ways: by type, application, configuration, end user and component. Revenue does not add across them: each is a different cut of the same total.
All two type lines expand in revenue terms over the forecast period. Share is the dividing line; one takes it, the other cedes it.
By Type · 2 segments
Partial Ring PET Scanners Outpaces the Axis While Full Ring PET Scanners Holds the Largest Share
- Largest Full Ring PET Scanners · 68%
- Fastest Partial Ring PET Scanners · 10.1%
- Moves most Full Ring PET Scanners · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Full Ring PET Scanners | $4.69B | 68% | $9.16B | 64%-4 | 7.7% |
| Partial Ring PET Scanners | $2.21B | 32% | $5.15B | 36%+4 | 10.1% |
Full Ring PET Scanners lead because their continuous detector ring delivers higher sensitivity and image resolution, which academic medical centers and cancer hospitals prioritize for complex oncology staging. Partial Ring PET Scanners grow fastest as community hospitals and smaller diagnostic centers adopt lower-cost configurations that still meet routine clinical imaging needs without the capital outlay of a full-ring system. Full Ring PET Scanners remains the largest line through 2034, so the axis changes in proportion, not in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Application · 3 segments
Oncology Holds the Largest Application Share and Is Still the Quickest to Grow
- Largest Oncology · 62%
- Fastest Oncology · 9%
- Moves most Oncology · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Oncology | $4.28B | 62% | $9.30B | 65%+3 | 9% |
| Cardiology | $1.66B | 24.1% | $3.15B | 22%-2.1 | 7.4% |
| Others | $0.96B | 13.9% | $1.86B | 13%-0.9 | 7.6% |
Oncology leads and grows fastest because PET imaging's core clinical value lies in detecting, staging and monitoring cancer treatment response, a use case reimbursed consistently across major health systems. Cardiology relies on PET for viability and perfusion studies in a narrower patient population, while other applications, including neurology and infection imaging, remain a smaller, more specialized share of total scan volume. Oncology remains the largest line through 2034, so the axis changes in proportion, not in order.
By Configuration · 3 segments
PET/MRI Hybrid Systems Outpaces the Axis While PET/CT Hybrid Systems Holds the Largest Share
- Largest PET/CT Hybrid Systems · 78%
- Fastest PET/MRI Hybrid Systems · 15.8%
- Moves most PET/MRI Hybrid Systems · +8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| PET/CT Hybrid Systems | $5.38B | 78% | $10.59B | 74%-4 | 7.8% |
| Standalone PET Systems | $0.83B | 12% | $1.14B | 8%-4 | 3.6% |
| PET/MRI Hybrid Systems | $0.69B | 10% | $2.58B | 18%+8 | 15.8% |
PET/CT Hybrid Systems lead because combining anatomical and functional imaging in one exam has become the clinical standard for oncology workups, letting radiologists localize findings precisely. PET/MRI Hybrid Systems grow fastest as cancer and neurology centers value their soft-tissue contrast and lower radiation exposure for pediatric patients and repeat scans, even as standalone PET systems remain in use for cost-sensitive settings. By 2034 PET/CT Hybrid Systems is still ahead, making this a shift in weight, not a change of leader.
By End User · 3 segments
Diagnostic Imaging Centers Outpaces the Axis While Hospitals Holds the Largest Share
- Largest Hospitals · 58%
- Fastest Diagnostic Imaging Centers · 9.5%
- Moves most Hospitals · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals | $4B | 58% | $7.87B | 55%-3 | 7.8% |
| Diagnostic Imaging Centers | $2.21B | 32% | $5.01B | 35%+3 | 9.5% |
| Academic & Research Institutes | $0.69B | 10% | $1.43B | 10% | 8.4% |
Hospitals lead because most PET systems are capital equipment purchased by multi-specialty health systems with the referral volume and staffing to justify the investment. Diagnostic Imaging Centers grow fastest as outpatient referral networks expand access to PET scanning outside hospital campuses, particularly for routine oncology follow-up, while academic and research institutes remain a smaller, specialized buyer group. The order does not change: Hospitals is still largest in 2034, and what moves is how much it holds.
By Component · 3 segments
Scale in Systems (Hardware) and Growth in Software & Reconstruction Solutions Define the Component Axis
- Largest Systems (Hardware) · 72%
- Fastest Software & Reconstruction Solutions · 13.5%
- Moves most Systems (Hardware) · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Systems (Hardware) | $4.97B | 72% | $9.44B | 66%-6 | 7.4% |
| Software & Reconstruction Solutions | $0.69B | 10% | $2.15B | 15%+5 | 13.5% |
| Services & Maintenance | $1.24B | 18% | $2.72B | 19%+1 | 9.1% |
Systems revenue leads because the scanner itself represents the majority of any purchase decision's cost, with software and services layered on afterward. Software and Reconstruction Solutions grow fastest as providers pay for AI-assisted image reconstruction and quantification upgrades that extend the useful life of installed hardware. Services and Maintenance grow steadily as the installed base of systems requiring upkeep expands. The order does not change: Systems (Hardware) is still largest in 2034, and what moves is how much it holds.
Regional Insights
Regional Revenue Share
Base year 2025
Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 4 points of share move elsewhere by 2034, while revenue still grows 1.9×.
- Rank 1 of 5
- 2025 share 38%
- By 2034 34%
- Revenue $2.62B → $4.87B
USD 2.62 billion of 2025 revenue is generated in North America, 38% of the global nuclear medicine imaging equipment market rising to USD 4.87 billion in 2034. Among the five regions it ranks first by revenue in both years.
Its share moves to 34% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Within the region the type split tracks the global one; 68% of 2025 revenue in Full Ring PET Scanners, fastest growth of 10.13% in Partial Ring PET Scanners. The full report breaks North America out along every axis and by country.
United States
Sets the pace for North America at 85.1% of it, growing 1.9×.
- In region 1 of 2
- Of region 85.1%
- Of global 32.3%
- Revenue $2.23B → $4.14B
USD 2.23 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 4.14 billion by 2034. At 85.1% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 2.62 billion to USD 4.87 billion over the same period, and this is the market carrying the country-level detail in the full report.
the United States buys along the same lines as the market globally; Full Ring PET Scanners first at 68% of 2025 revenue and 64% in 2034, Partial Ring PET Scanners fastest at 10.13% on a share moving from 32% to 36%. Its 85.1% weight in North America means those movements carry straight into the regional totals. Revenue by type for the United States is reported separately in the full report.
Nuclear medicine imaging equipment sold in the United States is regulated by the Food and Drug Administration under its medical device framework, administered through the Center for Devices and Radiological Health. A gamma camera, SPECT or PET system is classified according to its risk profile, and most such systems reach the market through the premarket notification pathway by demonstrating substantial equivalence to a predicate device already cleared for sale. Manufacturers must also meet the agency's performance standards for radiation-emitting products, covering aspects such as dose output and shielding. Facilities operating this equipment fall under additional oversight from state radiation control programs and, where radioactive materials are involved, from the Nuclear Regulatory Commission. Labelling must disclose intended use, operating parameters and safety warnings clearly enough for a qualified operator to rely on.
Digirad Corp. (US), Philips Healthcare (US), GE Healthcare Plc (UK), Mediso Medical Imaging Systems (Hungary), Siemens Healthineers (Germany) and Positron Corporation (US) are the suppliers covered in the United States. Full Ring PET Scanners, at 68% of 2025 revenue, is where the volume sits, and Partial Ring PET Scanners, growing at 10.13%, is where position changes hands over the forecast period. The full report covers country-level positioning and shares company by company; this summary does not.
Canada
2nd-largest in North America, growing 1.9×.
- In region 2 of 2
- Of region 14.5%
- Of global 5.5%
- Revenue $0.38B → $0.72B
Within North America, Canada accounts for 14.5% of regional revenue and 5.5% of the global total, worth USD 0.38 billion in 2025 and USD 0.72 billion by 2034.
Europe Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 1.9×.
- Rank 2 of 5
- 2025 share 27%
- By 2034 25%
- Revenue $1.86B → $3.58B
27% of the global nuclear medicine imaging equipment market sits in Europe in 2025, worth USD 1.86 billion with USD 3.58 billion projected for 2034. Among the five regions it ranks second by revenue in both years.
25% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
Segment composition follows the global pattern: Full Ring PET Scanners largest at 68% of 2025 revenue, Partial Ring PET Scanners fastest at 10.13%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 1.9×.
- In region 1 of 3
- Of region 30.1%
- Of global 8.1%
- Revenue $0.56B → $1.07B
USD 0.56 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 1.07 billion by 2034. At 30.1% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. The region itself runs USD 1.86 billion to USD 3.58 billion over the same period, and this is the market carrying the country-level detail in the full report.
The type pattern in Germany is the global one: 68% of 2025 revenue in Full Ring PET Scanners, 64% by 2034, against 10.13% growth in Partial Ring PET Scanners taking it from 32% to 36%. Since 30.1% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Germany carries its own type breakdown in the full report.
As a European Union member state, Germany regulates nuclear medicine imaging equipment under the EU Medical Device Regulation, which classifies such systems according to their risk and function and requires conformity assessment before a CE mark can be applied. A notified body, often operating within Germany itself, reviews technical documentation, quality management systems and clinical evaluation evidence for higher-risk imaging devices. The Federal Institute for Drugs and Medical Devices oversees market surveillance and vigilance reporting once a device is placed on the German market. Because these systems involve ionising radiation, installations must also satisfy national radiation protection law, which governs licensing of the equipment's use and the training of operating personnel. Labelling and instructions for use must appear in German and follow the harmonised standards referenced under the Regulation.
In Germany the field is Digirad Corp. (US), Philips Healthcare (US), GE Healthcare Plc (UK), Mediso Medical Imaging Systems (Hungary), Siemens Healthineers (Germany) and Positron Corporation (US). Volume sits in Full Ring PET Scanners at 68% of 2025 revenue; movement sits in Partial Ring PET Scanners at 10.13% growth. The commercial size of that position is USD 1.86 billion in 2025 and USD 3.58 billion by 2034, 27% of the global total in the base year.
United Kingdom
2nd-largest in Europe, growing 1.9×.
- In region 2 of 3
- Of region 22%
- Of global 5.9%
- Revenue $0.41B → $0.79B
Within Europe, the United Kingdom accounts for 22% of regional revenue and 5.9% of the global total, worth USD 0.41 billion in 2025 and USD 0.79 billion by 2034.
France
3rd-largest in Europe, growing 1.9×.
- In region 3 of 3
- Of region 17.7%
- Of global 4.8%
- Revenue $0.33B → $0.64B
France is sized at USD 0.33 billion in 2025, rising to USD 0.64 billion by 2034; 4.8% of global revenue and 17.7% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 5.9 points of share by 2034, while revenue still grows 2.6×.
- Rank 3 of 5
- 2025 share 24.1%
- By 2034 30%
- Revenue $1.66B → $4.29B
USD 1.66 billion of 2025 revenue is generated in Asia Pacific, 24.1% of the global nuclear medicine imaging equipment market and reaches USD 4.29 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.
Share climbs to 30% by 2034, on growth above the market's own 8.51%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Segment composition follows the global pattern: Full Ring PET Scanners largest at 68% of 2025 revenue, Partial Ring PET Scanners fastest at 10.13%. Per-axis and per-country detail for Asia Pacific sits in the full report.
China
The largest market in Asia Pacific, growing 2.6×.
- In region 1 of 3
- Of region 39.8%
- Of global 9.6%
- Revenue $0.66B → $1.72B
China is the largest market within Asia Pacific, generating USD 0.66 billion in 2025 and projected to reach USD 1.72 billion by 2034. Its 39.8% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 1.66 billion in 2025 and USD 4.29 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
China buys along the same lines as the market globally; Full Ring PET Scanners first at 68% of 2025 revenue and 64% in 2034, Partial Ring PET Scanners fastest at 10.13% on a share moving from 32% to 36%. Since 39.8% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. China carries its own type breakdown in the full report.
Nuclear medicine imaging equipment in China is regulated by the National Medical Products Administration, which classifies medical devices by risk and assigns imaging systems of this kind to its higher classification tier given their reliance on ionising radiation and diagnostic function. A supplier must obtain registration approval from the agency before marketing such a device, supported by technical files, clinical evaluation data and manufacturing quality certification aligned with national good manufacturing practice requirements. Because these systems emit or rely on radioactive materials, additional licensing from health and radiation safety authorities applies to their installation and operation within hospitals. Imported systems generally face a more demanding registration route than domestically produced equivalents, and labelling must be presented in Chinese with instructions that meet the administration's format requirements.
Digirad Corp. (US), Philips Healthcare (US), GE Healthcare Plc (UK), Mediso Medical Imaging Systems (Hungary), Siemens Healthineers (Germany) and Positron Corporation (US) are the suppliers covered in China. Full Ring PET Scanners, at 68% of 2025 revenue, is where the volume sits, and Partial Ring PET Scanners, growing at 10.13%, is where position changes hands over the forecast period. A supplier weighted toward Asia Pacific is competing over a base of USD 1.66 billion in 2025 reaching USD 4.29 billion by 2034, 24.1% of global revenue at the start of that period.
Japan
2nd-largest in Asia Pacific, growing 2.6×.
- In region 2 of 3
- Of region 30.1%
- Of global 7.2%
- Revenue $0.50B → $1.29B
7.2% of global revenue is generated in Japan; USD 0.5 billion in 2025, reaching USD 1.29 billion in 2034, and 30.1% of Asia Pacific.
India
3rd-largest in Asia Pacific, growing 2.6×.
- In region 3 of 3
- Of region 15.1%
- Of global 3.6%
- Revenue $0.25B → $0.64B
India is sized at USD 0.25 billion in 2025, rising to USD 0.64 billion by 2034; 3.6% of global revenue and 15.1% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 2.1×.
- Rank 4 of 5
- 2025 share 5.9%
- By 2034 5.9%
- Revenue $0.41B → $0.85B
In Latin America, 5.9% of global revenue puts 2025 at USD 0.41 billion and reaches USD 0.85 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.
By 2034 the share stands at 5.9%, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Full Ring PET Scanners leads here as it does globally, at 68% of 2025 revenue, and Partial Ring PET Scanners again grows fastest at 10.13%. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 2.0×.
- In region 1 of 2
- Of region 56.1%
- Of global 3.3%
- Revenue $0.23B → $0.47B
Brazil is the largest market within Latin America, generating USD 0.23 billion in 2025 and projected to reach USD 0.47 billion by 2034. At 56.1% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Against regional totals of USD 0.41 billion in 2025 and USD 0.85 billion in 2034, it is the country the full report breaks out in detail.
Composition here matches the global split: the largest line is Full Ring PET Scanners at 68% of 2025 revenue, easing to 64% by 2034, and the fastest is Partial Ring PET Scanners at 10.13%, from 32% to 36%. Because the country carries 56.1% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-type revenue for Brazil appears on its own in the full report.
In Brazil, nuclear medicine imaging equipment falls under the authority of the National Health Surveillance Agency, known as Anvisa, which treats such systems as medical devices requiring registration before commercial distribution. Classification follows a risk-based scheme, and imaging equipment of this kind typically requires a more rigorous technical dossier covering safety, performance and quality system compliance, often assessed against Brazil's own good manufacturing practice certification for the manufacturing site. Because the equipment involves ionising radiation, its installation and use are additionally subject to oversight from the national nuclear energy authority, which licenses radiation sources and inspects facilities. Portuguese-language labelling and user documentation are required, and any post-market safety issue must be reported to Anvisa under its vigilance system.
In Brazil the field is Digirad Corp. (US), Philips Healthcare (US), GE Healthcare Plc (UK), Mediso Medical Imaging Systems (Hungary), Siemens Healthineers (Germany) and Positron Corporation (US). The commercially relevant division is 68% of 2025 revenue in Full Ring PET Scanners, where the volume is, against 10.13% growth in Partial Ring PET Scanners, where share moves. That makes Latin America a 5.9% share of 2025 global revenue, USD 0.41 billion rising to USD 0.85 billion, for any supplier deciding where to concentrate.
Mexico
2nd-largest in Latin America, growing 2.0×.
- In region 2 of 2
- Of region 36.6%
- Of global 2.2%
- Revenue $0.15B → $0.30B
Mexico is sized at USD 0.15 billion in 2025, rising to USD 0.3 billion by 2034; 2.2% of global revenue and 36.6% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered — 0.1 points of share move elsewhere by 2034, while revenue still grows 2.1×.
- Rank 5 of 5
- 2025 share 5.1%
- By 2034 5%
- Revenue $0.35B → $0.72B
Middle East and Africa holds 5.1% of the global nuclear medicine imaging equipment market in 2025, worth USD 0.35 billion and reaches USD 0.72 billion by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
Its share moves to 5% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Segment composition follows the global pattern: Full Ring PET Scanners largest at 68% of 2025 revenue, Partial Ring PET Scanners fastest at 10.13%. The full report breaks Middle East and Africa out along every axis and by country.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.1×.
- In region 1 of 2
- Of region 34.3%
- Of global 1.7%
- Revenue $0.12B → $0.25B
USD 0.12 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.25 billion by 2034. At 34.3% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Regional revenue of USD 0.35 billion in 2025 and USD 0.72 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Saudi Arabia buys along the same lines as the market globally; Full Ring PET Scanners first at 68% of 2025 revenue and 64% in 2034, Partial Ring PET Scanners fastest at 10.13% on a share moving from 32% to 36%. Its 34.3% weight in Middle East and Africa means those movements carry straight into the regional totals. Revenue by type for Saudi Arabia is reported separately in the full report.
The Saudi Food and Drug Authority governs the registration and market entry of nuclear medicine imaging equipment in Saudi Arabia, applying a medical device classification system that treats such imaging systems according to their risk and diagnostic role. A supplier must register the device and its manufacturing facility with the authority, providing evidence of conformity to recognised international safety and performance standards before the equipment can be marketed or installed. Given the use of ionising radiation, separate licensing from the kingdom's nuclear and radiological regulatory body applies to facilities that install and operate the equipment, covering shielding, staff training and ongoing safety inspection. Labelling and instructions for use must be provided in Arabic alongside any other language used, and importers are expected to maintain a local authorised representative for regulatory correspondence.
Competition in Saudi Arabia runs between the suppliers this study tracks: Digirad Corp. (US), Philips Healthcare (US), GE Healthcare Plc (UK), Mediso Medical Imaging Systems (Hungary), Siemens Healthineers (Germany) and Positron Corporation (US). The commercially relevant division is 68% of 2025 revenue in Full Ring PET Scanners, where the volume is, against 10.13% growth in Partial Ring PET Scanners, where share moves. The commercial size of that position is USD 0.35 billion in 2025 and USD 0.72 billion by 2034, 5.1% of the global total in the base year.
South Africa
2nd-largest in Middle East and Africa, growing 2.0×.
- In region 2 of 2
- Of region 25.7%
- Of global 1.3%
- Revenue $0.09B → $0.18B
1.3% of global revenue is generated in South Africa; USD 0.09 billion in 2025, reaching USD 0.18 billion in 2034, and 25.7% of Middle East and Africa.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, configuration, end user, component, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Type Axis Decides Competitive Standing
The field covered here is Digirad Corp. (US), Philips Healthcare (US), GE Healthcare Plc (UK), Mediso Medical Imaging Systems (Hungary), Siemens Healthineers (Germany) and Positron Corporation (US).
The type axis, not the regional one, is where competition happens. 68% of 2025 revenue, worth USD 4.69 billion, is in Full Ring PET Scanners, still 64% of the total in 2034; that is the position least likely to change hands. Movement is concentrated in Partial Ring PET Scanners; 10.13% growth, against 7.67% at the other end of the axis in Full Ring PET Scanners. A supplier positioned in one is not automatically positioned in the other, so a field of this size stays viable in a market of USD 6.9 billion.
In nuclear medicine imaging equipment, scale in manufacturing and depth of regulatory approval experience across major markets separate the leading suppliers from the rest. The largest global manufacturers compete on breadth of installed base, service and maintenance network reach, and continued investment in digital detector and AI-based reconstruction technology that shortens scan times and improves image quality. Smaller and regional suppliers compete on price, faster local service response, and systems sized for lower-throughput or space-constrained facilities rather than matching the largest players on installed base or global service reach.
Geographic reach is the other axis of competition. North America alone accounts for 38% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 27%.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Nuclear Medicine Imaging Equipment Market Companies Profiled
6 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Digirad Corp. (US)
- Philips Healthcare (US)
- GE Healthcare Plc (UK)
- Mediso Medical Imaging Systems (Hungary)
- Siemens Healthineers (Germany)
- Positron Corporation (US)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Type, Application, Configuration, End User, Component), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 6 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Nuclear Medicine Imaging Equipment Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Nuclear Medicine Imaging Equipment Market Overview, By Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Nuclear Medicine Imaging Equipment Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Nuclear Medicine Imaging Equipment Market Overview, By Configuration, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Nuclear Medicine Imaging Equipment Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Nuclear Medicine Imaging Equipment Market Overview, By Component, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Nuclear Medicine Imaging Equipment Market Size — Segment Comparison
Chapter 22.Global Nuclear Medicine Imaging Equipment Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Nuclear Medicine Imaging Equipment Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Nuclear Medicine Imaging Equipment Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Nuclear Medicine Imaging Equipment Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Nuclear Medicine Imaging Equipment Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Nuclear Medicine Imaging Equipment Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Type
2- 01Full Ring PET Scanners
- 02Partial Ring PET Scanners
By Application
3- 01Oncology
- 02Cardiology
- 03Others
By Configuration
3- 01PET/CT Hybrid Systems
- 02Standalone PET Systems
- 03PET/MRI Hybrid Systems
By End User
3- 01Hospitals
- 02Diagnostic Imaging Centers
- 03Academic & Research Institutes
By Component
3- 01Systems (Hardware)
- 02Software & Reconstruction Solutions
- 03Services & Maintenance
Segment categories shown for scope reference. See the Summary tab for revenue share by By Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The market is built upward from the number of nuclear medicine imaging systems installed each year, split by ring configuration and hybrid type, multiplied against average selling prices for new placements and replacement units at each configuration. Radiopharmaceutical dose volumes and reimbursement-coded procedure counts are used to cross-check installed-base utilization assumptions. This bottom-up build is then checked against disclosed imaging-equipment segment revenue reported by major manufacturers and against customs data for PET and SPECT system shipments under the applicable harmonized trade codes. Where the two diverge, the unit volume or price assumption feeding the bottom-up build is corrected rather than the disclosed revenue figure.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research targets procurement and capital-equipment decision-makers inside hospital and diagnostic-imaging-center radiology departments, together with service and maintenance contract managers who track total cost of ownership across the installed base. Regulatory affairs staff at equipment manufacturers are consulted on approval timelines for new scanner configurations and radiopharmaceutical-compatible systems in each jurisdiction. Group purchasing organization and tender-office contacts are included where public procurement drives a meaningful share of placements. Sampling weights the United States, Germany, Japan and China, reflecting where installed-base scale and near-term placement volume are both concentrated, while adding contacts in Gulf and Southeast Asian markets where new imaging capacity is being built out.
Desk research draws on the FDA 510(k) clearance database for PET and SPECT system models, the EU's MDR conformity registers for CE-marked imaging equipment, and national health-ministry registries that publish installed PET/CT and SPECT/CT unit counts, including OECD health equipment statistics for cross-country comparison. Customs data under the harmonized code covering medical imaging apparatus is used to track cross-border equipment shipments. Nuclear regulatory authority registers of licensed cyclotron and radiopharmacy facilities inform radioisotope supply-side assumptions. Manufacturer annual reports and investor disclosures for imaging-equipment segments are used to size company-level revenue for the top-down check.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from the expected replacement timing of the current installed base, the pace at which new PET tracers beyond FDG-18 move from approval into routine ordering, and the rate at which reimbursement coverage for PET-guided oncology staging expands in markets where it is not yet universal. Near-term years are adjusted to normalize for a scan-volume backlog that built up during prior service disruptions and is now working through the system rather than representing a permanent step-change in demand. The forecast holds if cancer screening volumes continue rising and if capital budgets for imaging equipment are not constrained by broader healthcare spending cuts.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Forecast outputs are back-tested against the market's own recorded 2020-2024 growth to confirm the model reproduces historical movement before it is extended forward. Segment share shifts, including the pace at which hybrid PET/MRI systems gain share from PET/CT, are reviewed against clinical adoption patterns reported by radiology specialists rather than accepted from the volume model alone. Sensitivities are tested for a radioisotope supply disruption that delays procedure volumes and for slower-than-modeled reimbursement expansion in markets where PET-guided oncology staging is not yet standard practice, and the resulting range is compared against the base forecast before it is finalized.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is highest for installed-base and replacement-cycle estimates in the United States, Germany and Japan, where PET/CT ordering and reimbursement patterns are well documented. It is lower for adoption curves in emerging Asia Pacific and Latin American markets, where public installed-base counts are incomplete, and for the pace of PET/MRI uptake specifically, which is thin enough in several markets to require analogue-based estimation. A radioisotope supply disruption or an unexpected reimbursement policy reversal in a major market would be the most likely reasons to revise this forecast materially.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Nuclear Medicine Imaging Equipment Market projected to reach?
USD 14.31 Billion by 2034, CAGR 8.51%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 38% of global revenue through 2034.
05Which segment leads the market?
Full Ring PET Scanners is the largest line by type, at 68% of revenue in 2025.
06Who are the key companies profiled?
Digirad Corp. (US), Philips Healthcare (US), GE Healthcare Plc (UK), Mediso Medical Imaging Systems (Hungary), Siemens Healthineers (Germany), Positron Corporation (US). Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.